AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
R21 MALARIA ANTIGEN
5 registrations across 3 African markets— 5 active
Markets with R21 MALARIA ANTIGEN
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| R21 Malaria Vaccine (Recombinant, Adjuvanted) Solution For Injection | 🇰🇪Kenya | Serum Institute of India Pvt Limited | active | Dec 2028 |
| CYVAC SOLUTION; INJECTION | 🇿🇼Zimbabwe | SERUM INSTITUTE OF INDIA PVT LTD | active | Dec 2027 |
| CYVAC SOLUTION; INJECTION | 🇿🇼Zimbabwe | SERUM INSTITUTE OF INDIA PVT LTD | active | Dec 2027 |
| CYVAC - 1 Dose Solution for injection | 🇹🇿Tanzania | Serum Institute of India Limited | active | — |
| CYVAC - 2 Dose Solution for injection | 🇹🇿Tanzania | Serum Institute of India Limited | active | — |
R21 MALARIA ANTIGEN in Africa — Regulatory Overview
R21 MALARIA ANTIGEN is registered across 3 African markets with 5 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tanzania, Zimbabwe, Kenya. AfricaRegulatory refreshes this data daily from official government sources.
Of the 5 registrations, 5 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.